Nanomedicine: Transforming Neurological Therapies and Precision Medicine

Huma Ikram

Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Karachi, Pakistan

Abstract

Nanomedicine is going to be a novel and different avenue of therapy for the neurological patients, overcoming blood-brain barrier difficulties while also addressing the unique complexity of neurological diseases. With applications of nanoparticles, including liposomes, dendrimers, exosomes, and polymeric nanoparticles, effective drug delivery will be possible via targeted and controlled release and reduced adverse effects. These technological breakthroughs are going to be of great help in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's, and in conditions like multiple sclerosis. Because of this, nanomedicine has a great promise in the field of neuroinflammatory conditions as well. In addition, nanomedicine is going to play a significant role in precision medicine, where therapies can be planned according to the genetic, molecular, and biological makeup of the patients. However, precision in diagnosis and monitoring will also provide a personalized treatment regimen as nanotechnology can be integrated with other advanced diagnostic technologies like MRI, PET, and biomarker detection. Although it has a lot of promise, clinical translation has not avoided the same problems that have proved to be highly disconcerting for so many developments in nanomedicine, including issues of biocompatibility, safety, and, in the case of some products, regulatory approval. Addressing these factors will prove critical for the successful embedding of nanomedicine into the routine neurological care system. This review touches on the current status of nanomedicine in neurology, the promise that it holds for precision treatments, and the barriers that apply to its ability to effect real clinical practice portrayals, thereby providing an insight into the future of personalized therapy in neurology.

Nanomedicine in Neurology

Nanomedicine indeed has more to offer to neurology than merely detecting and treating neurological disorders. For example, the use of nanostructures across the blood-brain barrier would perhaps allow drug delivery systems to favourably alter the therapy of Alzheimer's and Parkinson's disease by not directing the drug away from brain tissues.¹ Recent studies in this area have demonstrated such an ability to improve therapeutics in the central nervous system via nanoscale modification. Nanotechnology has also paved the way for tools that would provide accurate imaging of neural tissues for early diagnosis and personalized therapy.^2,3 Moreover, research studies consider the various aspects of central nervous system diseases using nanomedicine strategies in this regard, taking into account the attributes that make it an ideal method to precisely deliver therapeutics across the blood-brain barrier.^4,5 Undoubtedly, these developments indicate how nanomedicine impacts achieving neurology-specific therapies and precision medicine.

Advancements in Nanotechnology for Neurological Disorders

Nanotechnology has made advancements in how most neurological disorders are treated. These innovations include drug delivery, diagnosis, and tissue repair. Nanocarriers, including liposomes and dendrimers, cross the blood-brain barrier for targeted therapies with minimal systemic toxicity.⁶ Magnetic nanoparticles facilitate nebular repair and neuromodulation.⁷ Graphene-based brain implants will advance neural interfaces benefiting Parkinson's disease and stroke patients.⁸ Nanotechnology can also lead to early detection using very sensitive diagnosis tools.⁹ Such advances underline the potential of nanotechnology to revolutionize treatments for some of the most complex neurological diseases.

Nanomedicine in Drug Delivery Systems

Nanomedicine is in the process of being developed for the brain-targeting drug delivery in overcoming blood-brain barrier-related hurdles. Nanoparticles like liposomes and polymeric carriers help in delivering therapeutic agents in a targeted manner, thereby increasing efficacy while minimizing systemic toxicity.¹⁰ Furthermore, magnetic and gold nanoparticles can offer targeted delivery, possibly using external guidance or stimuli. Exosomes provide a natural nanocarrier with good biocompatibility and also permeability through the BBB.^11,12 Besides that, multifunctional nanoparticles also assist the therapeutic applications, combining treatment with imaging.^13,14 These advances may provide a favourable opportunity to battle neurological disorders, including Alzheimer's and glioblastoma.

Nanoparticles for Targeted Treatment

Nanoparticles reveal such an enormous potential for the targeted treatment of neurological diseases by enabling targeted drug delivery across the blood-brain barrier (BBB). Engineered nanocarriers such as liposomes, polymeric nanoparticles, and dendrimers ensure drug delivery to specific regions of the brain while keeping systemic side effects to a minimum.^15,16 The presence of gold and magnetic nanoparticles serves a dual purpose-the transfer of therapeutics and imaging for real-time monitoring purposes.¹⁷ New emerging technologies such as exosomes and biomimetic carriers have increased biocompatibility and targeting efficiency.¹⁸ Such advancements are truly vital for treating complicated neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and glioblastoma, while ongoing research will lead to more efficient and customizable therapeutic options.

Nanodiagnostics

Nanodiagnostics is redefining early detection and imaging by providing nanoscale technologies with unprecedented ability to identify diseases. Nanoparticles, quantum dots, and nanosensors have enhanced the sensitivity of diagnostic tools to detect biomarkers at low concentrations.^19-21 These innovations have a great impact in cancer, neurological disorders, and infectious diseases, as early intervention produces better outcomes. Advanced nanomaterials like gold and magnetic nanoparticles also facilitate high-resolution imaging and help localize pathological changes.^22,23 Claiming to be further enhanced with machine learning and personalized medicine doubly positions nanodiagnostics toward becoming another disruptive force for the management of disease, redefining the future of health care.

Precision Medicine in Neurology

Nanotechnology is completely changing the face of precision medicine in neurology, offering more personalized approaches to treatment and diagnosis. Nanoparticles, including liposomes and polymeric carriers, facilitate targeted drug delivery across the blood-brain barrier while minimizing systemic-side effects and improving therapeutic effectiveness.^24,25 On the front of nanodiagnostics, quantum dots and nanosensors afford new avenues for early detection of neurological biomarkers, which is critical in conditions such as Alzheimer’s and Parkinson’s disease.²⁶ Nanostructural scaffolds also facilitate neural regeneration, therefore assisting recovery associated with neurotrauma.²⁷ Collectively, nanotechnology, genomics, and artificial intelligence serve as a platform for creating personalized treatment strategies, thus enhancing the fight against complex neurological disorders with further precision and favourable outcome for the patient.

Challenges in Nanomedicine for Neurological Applications

There are still difficult problems in nanomedicine for neurological purposes, foremost being the permeation of the blood-brain barrier (BBB), that inhibits drug delivery to the brain. It continues to be a significant challenge to construct nanoparticles that can rapidly and safely permeate the BBB without being toxic.^28-30 Furthermore, the biocompatibility and biodegradability of the nanoparticles must not cause any adverse effects in the future. Such nanomedicines are even more difficult to design as precise targeting of certain areas of the brain for therapy is needed. Moreover, the regulatory problems on the approval of nanomedicines because of the breakthrough technologies, adds more problems, hence requiring more time for clinical application of these therapies for neurological disorders.^31,32

Regulatory and Ethical Considerations

Nanomedicine, or the application of nanotechnology for diagnostic, therapeutic, and monitoring purposes in medicine, has raised regulatory and ethical matters regarding its safety, efficacy, and public trust. Due to their unique properties and complexity, regulatory agencies as FDA, finds difficult as they lack guidelines regarding the standards for such nanoparticle based therapies.^33,34 The long-term impact of nanomaterials on human health and the environment is still not well understood and therefore requires comprehensive testing of safety. Ethical issues include patient consent, privacy, and access to high-tech treatments such as personalized nanomedicine.³⁵ Addressing equity, precaution and regulation is crucial to the responsible development and integration of nanomedicine into health care.

Future Directions and Emerging Trends

Nanomedicine for neurology will bring immense promise through emerging trends which focus on precise treatments and methods for early detection and personalized medicines. Scientists develop new nanoparticle designs to break through the blood-brain barrier (BBB) while delivering drugs specifically to brains suffering from neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.^36-38 Exosomes and biodegradable nanoparticles represent two new nanomaterials that provide both secure therapeutic outcomes and enhanced brain treatment benefits. Theranostic allows researchers to develop nanoparticles which perform both diagnostic and therapeutic functions while monitoring treatment development in real-time according to reports.^39,40 The convergence of nanomedicine with artificial intelligence and gene therapy demonstrates potential advancements for tailored neurological treatments that could transform clinical practice.

Conclusion

In conclusion, nanomedicine revolutionizes brain disease diagnosis and treatment through innovative understandings of complex neurological conditions in precision medicine practices. Advanced nanocarriers paired with diagnostic tools in nanomedicine lead to precise drug delivery and better imaging capabilities and faster detection which generate more effective therapy while cutting down adverse effects. Research into nano-therapeutics allows scientists to investigate novel treatment strategies for brain diseases through better tumor management and meaningful care improvements while navigating the blood-brain barrier successfully. Nanotechnology research in combination with personalized medicine continues to refine neurological treatment methods which establishes better targeted and individualized care approaches.

References

1. Vashist A, Manickam P, Raymond AD, et al. Recent Advances in Nanotherapeutics for Neurological Disorders. ACS Appl Bio Mater. 2023; 6(7): 2614-2621.
2. Sim TM, Tarini D, Dheen ST, et al. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders. Int J Mol Sci. 2020; 21(17): 6070.
3. Nguyen TT, Dung Nguyen TT, Vo TK, et al. Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother. 2021; 143(1): 112117.
4. Jena L, McErlean E, McCarthy H. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme. Drug Deliv Transl Res. 2020; 10(2): 304-318.
5. Jagaran K, Singh M. Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases. Int J Mol Sci. 2021; 22(16): 9082.
6. Mohapatra P, Gopikrishnan M, Doss C GP, et al. How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier A Comprehensive Review of the Literature. Int J Nanomedicine. 2024; 19(1): 2441-2467.
7. Velazquez-Albino AC, Imhoff ED, Rinaldi-Ramos CM. Advances in engineering nanoparticles for magnetic particle imaging (MPI). Sci Adv. 2025; 11(2): eado7356.
8. Sisubalan N, Shalini R, Ramya S, et al. Recent advances in nanomaterials for neural applications: opportunities and challenges. Nanomedicine (Lond). 2023; 18(26): 1979-1994.
9. Thwala LN, Ndlovu SC, Mpofu KT, et al. Nanotechnology-Based Diagnostics for Diseases Prevalent in Developing Countries: Current Advances in Point-of-Care Tests. Nanomaterials (Basel). 2023; 13(7): 1247.
10. Dristant U, Mukherjee K, Saha S, et al. An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment. Technol Cancer Res Treat. 2024; 23 (1): 15330338241276300.
11. Gessner I, Park JH, Lin HY, et al. Magnetic Gold Nanoparticles with Idealized Coating for Enhanced Point-Of-Care Sensing. Adv Healthc Mater. 2022; 11(2): e2102035.
12. Soleymani S, Doroudian M, Soezi M, et al. Engendered nanoparticles for treatment of brain tumors. Oncol Res. 2024; 33(1): 15-26.
13. Jiang X, Lin W. Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy. Angew Chem Int Ed Engl. 2025. doi:10.1002/anie.202423280
14. Xi W, Wu W, Zhou L, et al. Multifunctional nanoparticles confers both multiple inflammatory mediators scavenging and macrophage polarization for sepsis therapy. Mater Today Bio. 2024; 30(1): 101421.
15. Pinheiro RGR, Coutinho AJ, Pinheiro M, et al. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? Int J Mol Sci. 2021; 22(21): 11654.
16. Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol. 2023; 11(1): 1177151.
17. Gupta D, Roy P, Sharma R, et al. Recent nanotheranostic approaches in cancer research. Clin Exp Med. 2024; 24(1): 8.
18. Wang X, Zhao X, Zhong Y, et al. Biomimetic Exosomes: A New Generation of Drug Delivery System. Front Bioeng Biotechnol. 2022; 10(1): 865682.
19. Darvishi M, Amiri R, Ghannad E, et al. Nanodiagnostics in global eradication of hepatitis C virus. Clin Chim Acta. 2025; 565(1): 120013.
20. Baghban R, Namvar E, Attar A, et al. Progressing nanotechnology to improve diagnosis and targeted therapy of Diabetic Retinopathy. Biomed Pharmacother. 2025. doi:10.1016/j.biopha.2024.117786
21. Choi HK, Yoon J. Nanotechnology-Assisted Biosensors for the Detection of Viral Nucleic Acids: An Overview. Biosensors (Basel). 2023; 13(2): 208.
22. Mukherjee S, Liang L, Veiseh O. Recent Advancements of Magnetic Nanomaterials in Cancer Therapy. Pharmaceutics. 2020; 12(2): 147.
23. Stueber DD, Villanova J, Aponte I, et al. Magnetic Nanoparticles in Biology and Medicine: Past, Present, and Future Trends. Pharmaceutics. 2021; 13(7): 943.
24. Toader C, Dumitru AV, Eva L, et al. Nanoparticle Strategies for Treating CNS Disorders: A Comprehensive Review of Drug Delivery and Theranostic Applications. Int J Mol Sci. 2024; 25(24): 13302.
25. Razavi R, Khajouei G, Divsalar F, et al. Recent advances on brain drug delivery via nanoparticles: alternative future materials for neuroscience applications; a review. Rev Neurosci. 2025. doi:10.1515/revneuro-2024-0086.
26. Chen CH, Liang HH, Wang CC, et al. Unlocking early detection of Alzheimer's disease: The emerging role of nanomaterial-based optical sensors. J. Food Drug Anal. 2024; 32(3): 296-324.
27. Yang Q, Lu D, Wu J, et al. Nanoparticles for the treatment of spinal cord injury. Neural Regen Res. 2025; 20(6): 1665-1680.
28. Dong N, Ali-Khiavi P, Ghavamikia N, et al. Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology. Neurol Sci. 2024. doi: 10.1007/s10072-024-07871-4.
29. Kulkarni M, Patel K, Patel A, et al. Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review. ADMET DMPK. 2023; 12(1): 63-105.
30. Anwarkhan S, Koilpillai J, Narayanasamy D. Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies. Cureus. 2024; 16(9): e68419.
31. Havelikar U, Ghorpade KB, Kumar A, et al. Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines. Discov Nano. 2024; 19(1): 165.
32. Halwani AA. Development of Pharmaceutical Nanomedicines: From the Bench to the Market. Pharmaceutics. 2022; 14(1): 106.
33. Csóka I, Ismail R, Jójárt-Laczkovich O, et al. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development. Curr Med Chem. 2021; 28(36): 7461-7476.
34. Ma X, Tian Y, Yang R, et al. Nanotechnology in healthcare, and its safety and environmental risks. J Nanobiotech. 2024; 22(1): 715.
35. Xuan L, Ju Z, Skonieczna M, et al. Nanoparticles-induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models. Med Comm. 2023; 4(4): e327.
36. Krsek A, Jagodic A, Baticic L. Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review. Medicina (Kaunas). 2024; 60(9): 1384.
37. Alghamdi MA, Fallica AN, Virzì N, et al. The Promise of Nanotechnology in Personalized Medicine. J Pers Med. 2022; 12(5): 673.
38. Sharma H, Narayanan KB, Ghosh S, et al. Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier. Biomimetics (Basel). 2025; 10(1): 25.
39. Siafaka PI, Okur NÜ, Karantas ID, et al. Current update on nanoplatforms as therapeutic and diagnostic tools: A review for the materials used as nanotheranostics and imaging modalities. Asian J Pharm Sci. 2021; 16(1): 24-46.
40. Zhu W, Wei Z, Han C, et al. Nanomaterials as Promising Theranostic Tools in Nanomedicine and Their Applications in Clinical Disease Diagnosis and Treatment. Nanomaterials (Basel). 2021; 11(12): 3346.